Damages return to haunt Boston in Johnson & Johnson patent case
This article was originally published in Clinica
A Delaware Jury has found that Boston Scientific's NIR stent - which the company no longer sells - infringes Johnson & Johnson's Palmaz patent. No monetary damages have yet been set. Further post-verdict motions and hearings and an appeal by Boston Scientific are also expected. The verdict followed a retrial of earlier litigation in which J&J was awarded damages of $324m in 2000.